Lineage Cell Therapeutics, Inc. (LCTX) operates as a biotechnology firm in the clinical trial phase, dedicated to pioneering innovative cell-based treatments for various degenerative conditions across the United States and globally. The company's pipeline features several key therapeutic candidates: OpRegen, a replacement therapy utilizing retinal pigment epithelium cells, is currently undergoing Phase I/IIa clinical trials to address dry age-related macular degeneration. OPC1, an oligodendrocyte progenitor cell therapy, is being evaluated in Phase I/IIa multicenter clinical studies for individuals suffering from acute spinal cord injuries. VAC2, an allogeneic cancer immunotherapy employing antigen-presenting dendritic cells, has advanced to Phase I clinical trials for the treatment of non-small cell lung cancer. Beyond its development pipeline, Lineage Cell Therapeutics also markets Renevia, a product designed for facial aesthetics. The company's research and development endeavors extend to exploring therapeutic solutions for a broader range of retinal and neurological disorders, as well as additional oncology indications. A strategic alliance exists between Lineage Cell Therapeutics, Inc. and Orbit Biomedical, Ltd. The organization, which was established in 1990 and is headquartered in Carlsbad, California, previously operated under the name BioTime, Inc. before rebranding in August 2019.